This proposal is based upon three hypotheses: 1) The effective antioxidant activity of propranolol in vivo is primarily attributable to its biotransformation into more potent metabolites rather than to propranolol itself. 2) Lysosomes (particularly from endothelial cells) are a major source of iron, which enhances vascular injury in response to free radicals, and that concentrating antioxidants within lysosomes may provide enhanced tissue protection. 3) Modulation of lysosomal iron stores prior to oxidant exposure will alter the extent of injury induced by the oxidative stress. The applicant will utilize a variety of techniques to monitor: free radical production and oxidative injury (ESR spin trapping, lipid peroxidation assays, and endogenous antioxidant quantification); iron mobilization (histochemically and biochemically); and tissue and cellular toxicity (cellular viability and myocardial function) to investigate the following specific aims: 1. Determine the antioxidant properties and potency of 4-hydroxypropranolol (HOP) and a-naphthoxylacetic acid (NLA) (the two major biotransformed metabolites of propranolol). 2. Determine the effectiveness of the major metabolites of d-propranolol on ischemia/reperfusion-induced injury (hemodynamics; oxyradical, nitric oxide, and lipid radical production; etc.). 3. Determine if d,l- and d-propranolol and their major metabolites accumulate within the endothelial cell acidic compartments, and the mechanism and timing of this accumulation. 4. Examine the role of lysosomes and lysosomal iron in endothelial cell oxidative injury induced in response to applied (H2O2) and endogenously-induced (anoxia/reoxygenation) oxidants, and the effect of treatment with propranolol and its major metabolites on nitric oxide production in vivo. The applicant suggests that even mild iron excess in vivo may predispose cardiovascular patients to further risk, and that the major metabolites of propranolol may be cardioprotective clinically, in part, due to potent antioxidant properties.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL036418-13
Application #
2735108
Study Section
Cardiovascular and Pulmonary Research A Study Section (CVA)
Project Start
1985-08-01
Project End
2000-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
13
Fiscal Year
1998
Total Cost
Indirect Cost
Name
George Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20052
Mak, I Tong; Zhang, Jingyun; Weglicki, William B (2002) Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide. Pharmacol Res 45:27-33
Dickens, Benjamin F; Weglicki, William B; Boehme, Patricia A et al. (2002) Antioxidant and lysosomotropic properties of acridine-propranolol: protection against oxidative endothelial cell injury. J Mol Cell Cardiol 34:129-37
Komarov, A M; Mak, I T; Weglicki, W B (2000) The origin of dinitrosyl-iron complex in endothelial cells. Ann N Y Acad Sci 899:407-10
Mak, I T; Komarov, A M; Kramer, J H et al. (2000) Protective mechanisms of Mg-gluconate against oxidative endothelial cytotoxicity. Cell Mol Biol (Noisy-le-grand) 46:1337-44
Mak, I T; Zhang, J; Weglicki, W B (2000) Cytoprotective properties of nisoldipine and amlodipine against oxidative endothelial cell injury. Ann N Y Acad Sci 899:403-6
Kramer, J H; Lightfoot, F G; Weglicki, W B (2000) Cardiac tissue iron: effects on post-ischemic function and free radical production, and its possible role during preconditioning. Cell Mol Biol (Noisy-le-grand) 46:1313-27
Loyevsky, M; Sacci Jr, J B; Boehme, P et al. (1999) Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol 91:105-14
Loyevsky, M; John, C; Dickens, B et al. (1999) Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators. Mol Biochem Parasitol 101:43-59
Komarov, A M; Mattson, D L; Mak, I T et al. (1998) Iron attenuates nitric oxide level and iNOS expression in endotoxin-treated mice. FEBS Lett 424:253-6
Mak, I T; Dickens, B F; Komarov, A M et al. (1997) Activation of the neutrophil and loss of plasma glutathione during Mg-deficiency--modulation by nitric oxide synthase inhibition. Mol Cell Biochem 176:35-9

Showing the most recent 10 out of 60 publications